Abstract
Rare alleles at the HRAS1 variable number of tandem repeats (VNTRs) locus have been implicated in breast cancer risk. Although many studies have showed that rare HRAS1 alleles may be associated with breast cancer risk, this relationship remains controversial. A meta-analysis was conducted to investigate the potential association between rare HRAS1 alleles and breast cancer risk. A database search found a total of 13 studies involving 1926 breast cancer cases and 2800 controls. Crude odds ratios (OR) and 95% confidence intervals (CI) were used to test the strength of association. When all the studies were combined into the meta-analysis, we found that breast cancer cases had a significantly higher frequency of rare alleles (OR = 2.03, 95% CI = 1.34, 3.10). In the subgroup analysis by race, we found that breast cancer cases had a significantly higher frequency of rare alleles (OR = 2.14, 95% CI = 1.37, 3.36) among Caucasians. In the subgroup analysis by study design, we found that breast cancer cases had a significantly higher frequency of rare alleles (OR = 2.47, 95% CI = 1.62, 3.79) among groups with hospital-based controls. In conclusion, this meta-analysis suggested that rare alleles at the HRAS1 VNTRs may contribute to breast cancer susceptibility. More population-based case–control studies were needed especially in Asians in the future.
Similar content being viewed by others
References
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108
Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP (2009) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360(20):2055–2065
Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, Hudis C, Butler J, Merkel D, Kristal A, Caan B, Michaelson R, Vinciguerra V, Del Prete S, Winkler M, Hall R, Simon M, Winters BL, Elashoff RM (2006) Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst 98(24):1767–1776
Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360(8):790–800
Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8(10):843–854
Krontiris TG, DiMartino NA, Colb M, Parkinson DR (1985) Unique allelic restriction fragments of the human Ha-ras locus in leukocyte and tumour DNAs of cancer patients. Nature 313(6001):369–374
Theillet C, Lidereau R, Escot C, Hutzell P, Brunet M, Gest J, Schlom J, Callahan R (1986) Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas. Cancer Res 46(9):4776–4781
Pluzhnikova GF, Serova OM, Kniazev PG, Fedorov SN, Novikov LB (1987) Joint amplification of c-myc and c-Ha-ras oncogenes in human breast and thyroid cancer cells. Eksp Onkol 9(2):15–17
Peto TE, Thein SL, Wainscoat JS (1988) Statistical methodology in the analysis of relationships between DNA polymorphisms and disease: putative association of Ha-ras-I hypervariable alleles and cancer. Am J Hum Genet 42(4):615–617
Nikiforova IF (1988) Amplification, rearrangement and expression of the c-myc and c-Ha-ras1 proto-oncogenes in patients with breast cancer. Eksp Onkol 10(1):17–20
White GR, Heighway J, Williams GT, Scott D (1988) Constitutional frequency of rare alleles of c-Ha-ras in breast cancer patients. Br J Cancer 57(5):526
Garcia I, Dietrich PY, Aapro M, Vauthier G, Vadas L, Engel E (1989) Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res 49(23):6675–6679
Kniazev PG, Serova OM, Babenko VI, Nikiforova IF, Gol’tseva AA, Pluzhnikova GF, Plutalov OV, Berlin Iu A, Shvarts EI (1990) Molecular nature of oncogene HRAS1 damage in human breast carcinoma: G—T transversion in codon 12 of one allele during deletion of other allele. Bioorg Khim 16(3):419–423
Nefedov MD, Gar’kavtsev IV, Rogaev EI (1990) Analysis of the association of inherited predisposition to breast cancer with c-Ha-ras-1 oncogene alleles. Genetika 26(12):2226–2231
Watson DM, Elton RA, Jack WJ, Dixon JM, Chetty U, Miller WR (1991) The H-ras oncogene product p21 and prognosis in human breast cancer. Breast Cancer Res Treat 17(3):161–169
Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ (1995) Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 221(6):706–718 discussion 718–720
Conway K, Edmiston S, Fried DB, Hulka BS, Garrett PA, Liu ET (1995) Ha-ras rare alleles in breast cancer susceptibility. Breast Cancer Res Treat 35(1):97–104
Weston A, Godbold JH (1997) Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect 105(Suppl 4):919–926
Ding S, Larson GP, Foldenauer K, Zhang G, Krontiris TG (1999) Distinct mutation patterns of breast cancer-associated alleles of the HRAS1 minisatellite locus. Hum Mol Genet 8(3):515–521
Schondorf T, Andrack A, Niederacher D, Scharl A, Becker M, Engel H, Gohring UJ (1999) H-ras gene amplification or mutation is not common in human primary breast cancer. Oncol Rep 6(5):1029–1033
Kannan K, Krishnamurthy J, Feng J, Nakajima T, Tsuchida N, Shanmugam G (2000) Mutation profile of the p53, fhit, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas. Int J Oncol 17(5):1031–1035
Ozer E, Sis B, Ozen E, Sakizli M, Canda T, Sarioglu S (2000) BRCA1, C-erbB-2, and H-ras gene expressions in young women with breast cancer. An immunohistochemical study. Appl Immunohistochem Mol Morphol 8(1):12–18
Kotsinas A, Gorgoulis VG, Zacharatos P, Mariatos G, Kokotas S, Liloglou T, Ikonomopoulos J, Zoumpourlis V, Kyroudi A, Field JK, Asimacopoulos PJ, Kittas C (2001) Additional characterization of a hexanucleotide polymorphic site in the first intron of human H-ras gene: comparative study of its alterations in non-small cell lung carcinomas and sporadic invasive breast carcinomas. Cancer Genet Cytogenet 126(2):147–154
Schondorf T, Rutzel S, Andrack A, Becker M, Hoopmann M, Breidenbach M, Gohring UJ (2002) Immunohistochemical analysis reveals a protective effect of H-ras expression mediated via apoptosis in node-negative breast cancer patients. Int J Oncol 20(2):273–277
Papadakis EN, Dokianakis DN, Spandidos DA (2003) Genetic analysis of H-ras intron-1 polymorphic and variable tandem repeat regions in human breast cancer. Int J Biol Markers 18(3):195–199
Tamimi RM, Hankinson SE, Ding S, Gagalang V, Larson GP, Spiegelman D, Colditz GA, Krontiris TG, Hunter DJ (2003) The HRAS1 variable number of tandem repeats and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 12(12):1528–1530
Gosse-Brun S, Sauvaigo S, Daver A, Page M, Lortholary A, Larra F, Bignon YJ, Bernard-Gallon D (1999) Specific H-Ras minisatellite alleles in breast cancer susceptibility. Anticancer Res 19(6B):5191–5196
Firgaira FA, Seshadri R, McEvoy CR, Dite GS, Giles GG, McCredie MR, Southey MC, Venter DJ, Hopper JL (1999) HRAS1 rare minisatellite alleles and breast cancer in Australian women under age forty years. J Natl Cancer Inst 91(24):2107–2111
Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N (1993) An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med 329(8):517–523
Garrett PA, Hulka BS, Kim YL, Farber RA (1993) HRAS protooncogene polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev 2(2):131–138
Hall JM, Huey B, Morrow J, Newman B, Lee M, Jones E, Carter C, Buehring GC, King MC (1990) Rare HRAS alleles and susceptibility to human breast cancer. Genomics 6(1):188–191
Barkardottir RB, Johannsson OT, Arason A, Gudnason V, Egilsson V (1989) Polymorphism of the c-Ha-ras-1 proto-oncogene in sporadic and familial breast cancer. Int J Cancer 44(2):251–255
Sheng ZM, Guerin M, Gabillot M, Spielmann M, Riou G (1988) c-Ha-ras-1 polymorphism in human breast carcinomas: evidence for a normal distribution of alleles. Oncogene Res 2(3):245–250
Saglio G, Camaschella C, Giai M, Serra A, Guerrasio A, Peirone B, Gasparini P, Mazza U, Ceppellini R, Biglia N et al (1988) Distribution of Ha-RAS-1 proto-oncogene alleles in breast cancer patients and in a control population. Breast Cancer Res Treat 11(2):147–153
Mackay J, Elder PA, Porteous DJ, Steel CM, Hawkins RA, Going JJ, Chetty U (1988) Partial deletion of chromosome 11p in breast cancer correlates with size of primary tumour and oestrogen receptor level. Br J Cancer 58(6):710–714
Honda K, Ishizaki K, Ikenaga M, Toguchida J, Inamoto T, Tanaka K, Ozawa K (1988) Increased frequency of specific alleles of the c-Ha-ras gene in Japanese cancer patients. Hum Genet 79(4):297–300
Corell B, Zoll B (1988) Comparison between the allelic frequency distribution of the Ha-ras 1 locus in normal individuals and patients with lymphoma, breast, and ovarian cancer. Hum Genet 79(3):255–259
Lidereau R, Escot C, Theillet C, Champeme MH, Brunet M, Gest J, Callahan R (1986) High frequency of rare alleles of the human c-Ha-ras-1 proto-oncogene in breast cancer patients. J Natl Cancer Inst 77(3):697–701
Robins J, Greenland S, Breslow NE (1986) A general estimator for the variance of the Mantel-Haenszel odds ratio. Am J Epidemiol 124(5):719–723
Lee SA, Lee KM, Park SK, Choi JY, Kim B, Nam J, Yoo KY, Noh DY, Ahn SH, Kang D (2007) Genetic polymorphism of XRCC3 Thr241Met and breast cancer risk: case-control study in Korean women and meta-analysis of 12 studies. Breast Cancer Res Treat 103(1):71–76
Lu C, Dong J, Ma H, Jin G, Hu Z, Peng Y, Guo X, Wang X, Shen H (2009) CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 116(3):571–575
Tang C, Chen N, Wu M, Yuan H, Du Y (2009) Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 117(2):391–399
Tao W, Wang C, Han R, Jiang H (2009) HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 114(2):371–376
Ryberg D, Tefre T, Ovrebo S, Skaug V, Stangeland L, Naalsund A, Baera R, Borresen AL, Haugen A (1990) Ha-ras-1 alleles in Norwegian lung cancer patients. Hum Genet 86(1):40–44
Pierce LM, Sivaraman L, Chang W, Lum A, Donlon T, Seifried A, Wilkens LR, Lau AF, Le Marchand L (2000) Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically diverse population. Cancer Epidemiol Biomarkers Prev 9(11):1199–1204
Klingel R, Mittelstaedt P, Dippold WG, Meyer zum Buschenfelde KH (1991) Distribution of Ha-ras alleles in patients with colorectal cancer and Crohn’s disease. Gut 32(12):1508–1513
Wyllie FS, Wynford-Thomas V, Lemoine NR, Williams GT, Williams ED, Wynford-Thomas D (1988) Ha-ras restriction fragment length polymorphisms in colorectal cancer. Br J Cancer 57(2):135–138
Weitzel JN, Ding S, Larson GP, Nelson RA, Goodman A, Grendys EC, Ball HG, Krontiris TG (2000) The HRAS1 minisatellite locus and risk of ovarian cancer. Cancer Res 60(2):259–261
Ryberg D, Heimdal K, Fossa SD, Borresen AL, Haugen A (1993) Rare Ha-ras1 alleles and predisposition to testicular cancer. Int J Cancer 53(6):938–940
Green M, Krontiris TG (1993) Allelic variation of reporter gene activation by the HRAS1 minisatellite. Genomics 17(2):429–434
Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N (2009) Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement. Hum Genet 125(2):131–151
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, C., Lv, GQ., Yu, XM. et al. Current evidence on the relationship between HRAS1 polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 128, 467–472 (2011). https://doi.org/10.1007/s10549-011-1344-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-011-1344-2